Study identifier:D0810C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Open Label, Study of the Safety and Tolerability of KU-0059436 in Combination with Gemcitabine in the Treatment of Patients With Advanced Solid Tumours
Pancreatic neoplasms
Phase 1
No
KU-0059436 (AZD2281)(PARP inhibitor), Gemcitabine
All
68
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Feb 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with gemcitabine chemotherapy for the treatment of pancreatic cancer.
Location
Location
Nashville, TN, United States
Location
New York, NY, United States
Location
Oxford, United Kingdom
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: 1 Gemcitabine + KU-0059436 | Drug: KU-0059436 (AZD2281)(PARP inhibitor) oral Other Name: Olaparib Drug: Gemcitabine intravenous injection Other Name: Gemzar® Other Name: Gemcitabine HCL |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.